Sequana Medical NV
XBRU:SEQUA
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.1), the stock would be worth €-3.84 (765% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.1 | €0.58 |
0%
|
| Industry Average | 14.1 | €-3.84 |
-765%
|
| Country Average | 13.8 | €-3.77 |
-752%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Sequana Medical NV
XBRU:SEQUA
|
43.1m EUR | -2.1 | -0.8 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
201.9B USD | 24.4 | 31 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD | 58.3 | 62.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD | 27.9 | 45.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
125B USD | 21.5 | 27.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.6B USD | 30.7 | 39.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.8B EUR | 17.4 | 22.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.6B USD | 39 | 49.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD | 18.5 | 28.6 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD | 28.3 | 46.8 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD | 15.7 | 18.4 |
Market Distribution
| Min | 1.8 |
| 30th Percentile | 10 |
| Median | 13.8 |
| 70th Percentile | 19.8 |
| Max | 598.6 |
Other Multiples
Sequana Medical NV
Glance View
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
